CAMBRIDGE, Mass., April 22, 2026 /PRNewswire/ -- Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 ...

Artificial intelligence (AI) is emerging as a transformative tool in drug discovery and development, influencing steps from target identification to clinical trial outcome analyses. Target ...

PandaOmics is a cloud-based software platform that applies artificial intelligence and bioinformatics techniques to multimodal omics and biomedical text data for therapeutic target and biomarker ...

The Warburg effect, a widely known characteristic of cancer cells, refers to the utilization of glycolysis under aerobic conditions for extended periods of time. Recent studies have revealed that ...

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Target-based vs phenotypic screening remains a central strategic question in modern drug discovery, particularly as research teams balance mechanistic clarity with biological relevance. Advances in ...

CAMBRIDGE, Mass., April 22, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, recently published a comprehensive ...